Skip to main content
. 2016 Nov 8;6:35533. doi: 10.1038/srep35533

Figure 5. AKI603 and imatinib synergistically inhibit proliferation of cells harboring T315I mutation.

Figure 5

(A) KBM5-T315I and 32D-T315I cells were treated with indicated concentration of AKI603 for 96 h. The cytostatic activity was measured by MTT assay. Data was the mean of three independent experiments. (B) The colony formation of KBM5-T315I and 32D-T315I cells treated with 0.078 μM AKI603, 0.078 μM imatinib or 0.078 μM AKI603 plus 0.078 μM imatinib for 10 days was analyzed. The statistical analysis of the colony formation assay is shown (mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Con; #p < 0.05, # #p < 0.01vs AKI). (C) Representative images are shown and the diameters of colonies were measured. The values from three independent experiments are presented in a box plot graph and the size distribution of the colonies is shown (mean ± SD, **p < 0.01, ***p < 0.001 vs. Con; #p < 0.05, # #p < 0.01vs AKI). AKI: AKI603.